Accessibility Menu
Acer Therapeutics logo

Acer Therapeutics

(NASDAQ) ACER

This security has been delisted. This page is retained for historical reference.

Acer Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.662023-11-20
Acer Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.34%USD 0.852023-11-13
1 month-20.19%USD 0.832023-10-20
3 month+0%USD 0.662023-08-22
Year to date-73.7%USD 2.512022-12-30
1 year-44.06%USD 1.182022-11-18
3 year-75.82%USD 2.732020-11-20
5 year-97.26%USD 24.102018-11-21
Since inception-93.43%USD 10.042017-09-20

ACER News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ACER Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

283.88%

Return on Capital

N/A

Return on Assets

-225.71%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$287.99K

Operating Income

-$27.42M

EBITDA

-$41.49M

Operating Cash Flow

-$38.82M

Capital Expenditure

-$138.40K

Free Cash Flow

-$38.95M

Cash & ST Invst.

$594.66K

Total Debt

$18.15M

Acer Therapeutics Performance Analysis

Acer Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,260,000N/A
20222022-12-31USD 0N/A
Acer Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Acer Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.08N/A
20222022-12-31USD -1.6654.4%
Acer Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-74.2%
Q12023-03-31-42.6%
Q22023-06-3057.1%
Q32023-09-30-81.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$371.79K

N/A

Gross Profit

$287.99K

N/A

Gross Margin

77.46%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

30

N/A

Net Income

-$14.73M

-195.3%

EBITDA

-$14.86M

-198.8%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$594.66K

-90.7%

Total Debt

$18.15M

+120.1%

Accounts Receivable

$0.00

N/A

Inventory

$5.20M

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$18.15M

+1101.7%

Return on Assets

-2.26%

N/A

Return on Invested Capital

3.36%

N/A

Free Cash Flow

-$16.00M

-75.9%

Operating Cash Flow

-$16.00M

-76.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMHVAmerican Hemp Ventures, Inc.
$0.98+0.00%
IMNNImunon, Inc.
$1.89-2.07%
SQZBSQZ Biotechnologies Company
$0.02+0.00%
ELEVElevation Oncology, Inc.
$0.37-2.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
ONDSOndas
$6.65-0.06%
SOFISoFi Technologies
$17.32-0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.